Who is sponsoring NCT04232345?

NCT04232345 is sponsored by AstraZeneca.

What drugs are being tested in NCT04232345?

Interventions in NCT04232345: AZD4831, Placebo.

What condition does NCT04232345 study?

NCT04232345 studies Heart Failure With Preserved Ejection Fraction (HFpEF).

Is NCT04232345 still recruiting?

NCT04232345 is currently completed. Last updated 1 April 2021.

Last reviewed 2021-04-01 · How we verify

NCT04232345

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Completed Phase 1 Last updated 1 April 2021

What this trial tests

Phase 1 trial testing AZD4831 in Heart Failure With Preserved Ejection Fraction (HFpEF) in 32 participants. Completed in 11 March 2021.

Timeline

16 January 2020

Primary endpoint
11 March 2021

11 March 2021

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	single
Primary purpose	treatment
Enrollment	32
Start date	16 January 2020
Primary completion	11 March 2021
Estimated completion	11 March 2021
Sites	1 location across United States

Drugs / interventions tested

AZD4831 — full drug profile →
Placebo

Conditions studied

Heart Failure With Preserved Ejection Fraction (HFpEF) — all drugs for Heart Failure With Preserved Ejection Fraction (HFpEF) →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 50, male only, with Heart Failure With Preserved Ejection Fraction (HFpEF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is randomized, single-blind, placebo-controlled Phase 1 study aimed to assess the safety and efficacy, pharmacokinetics and pharmacodynamics of multiple doses of oral AZD4831 in healthy Japanese and Chinese volunteers

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Redox signaling at the crossroads of human health and disease.
Zuo J, Zhang Z, Luo M, Zhou L, et al · · 2022 · cited 74× · PMID 35386842 · DOI 10.1002/mco2.127
Pathological mechanisms and crosstalk among various cell death pathways in cardiac involvement of systemic lupus erythematosus.
Wei J, Wang A, Li B, Li X, et al · · 2024 · cited 8× · PMID 39301029 · DOI 10.3389/fimmu.2024.1452678
Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat.
Sunnåker M, Leander J, Ericsson H. · · 2026 · PMID 42101107 · DOI 10.1002/prp2.70259
Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.
Sunnåker M, Bhattacharya C, Nelander K, Aurell M, et al · · 2024 · PMID 39495467 · DOI 10.1007/s40261-024-01402-x

Verify or expand the search:

Other trials of AZD4831

Trials testing the same drug.

NCT05638737 — A Study in Participants With Non-cirrhotic NASH With Fibrosis · Phase 2 · completed
NCT05457270 — A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Health · Phase 1 · completed
NCT05236543 — A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole · Phase 1 · completed
NCT04949438 — A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants · Phase 1 · completed
NCT05052710 — Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam · Phase 1 · completed

Other recruiting trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

Currently open trials in the same condition.

NCT06560762 — Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) · Phase 1 · recruiting
NCT05441839 — UK Heart Failure With Preserved Ejection Fraction · recruiting
NCT04822649 — Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition · NA · recruiting
NCT03876223 — Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04232345 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 1 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04232345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing